Rituximab is a humanized, chimeric monoclonal anti-CD20 antibody. Treatment with rituximab is considered an established, not experimental therapy for CAD, and involved physicians and nurses should be familiar with its administration, therapeutic and adverse effects and safety issues. In particular, they should be able to identify and manage any infusion-related side effects.